New ALS drug trial hopes to slow nerve damage

NCT ID NCT07369076

Recruiting now Disease control Sponsor: Nura Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called NB-4746 in 80 people with ALS. The goal is to see if it is safe, how it moves through the body, and whether it can reduce a marker of nerve damage (NfL) in the blood. Participants are randomly assigned to receive either NB-4746 or a placebo for up to 12 weeks, with an option to continue treatment for up to a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Contacts and locations

Show contact details

Locations

Calvery Health care Bethlehem
RECRUITING

Caulfield South, Victoria, 3162, Australia
Concord Repatriation General Hospital
RECRUITING

Concord, New South Wales, 2139, Australia
Flinders Medical Centre
RECRUITING

Bedford Park, South Australia, 5042, Australia
Genge Partners
RECRUITING

Montreal, Quebec, H4A 3T2, Canada
Neuroscience Research Australia
RECRUITING

Randwick, New South Wales, 2031, Australia

Contact Email: •••••@•••••
Perron Institute
RECRUITING

Nedlands, Western Australia, 6009, Australia
Royal Brisbane and Women's Hospital
RECRUITING

Brisbane, Queensland, 4029, Australia
Stan Cassidy Center for Rehabilitation
RECRUITING

Fredericton, New Brunswick, E3B 0C7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.